Equine Influenza Infection

Equine Infectious Diseases

Volumn , Issue , 2007, Pages 124-134

  Landolt, Gabriele A ^a   Townsend, Hugh G G ^b   Lunn, D Paul ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882546217     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2406-4.50017-X     Document Type: Chapter

References (260)

1. Ohwada K, Kitame F, Sugawara K, et al. Distribution of the antibody to influenza C virus in dogs and pigs in Yamagata Prefecture, Japan. Microbiol Immunol 1987, 31:1173-1180.
2. Wright PF, Webster RG Orthomyxoviruses, Field's Virology 2001, Lippincott-Raven, Philadelphia. ed 4.
3. Manuguerra JC, Hannoun C, Simon F, et al. Natural infection of dogs by influenza C virus: a serological survey in Spain. New Microbiol 1993, 16:367-371.
4. Lamb R, Krug R Orthomyxoviruses: the viruses and their replication, Field's Virology 2001, Lippincott-Raven, Philadelphia. ed 4.
5. Colman PM, Laver WG, Varghese JN, et al. Three-dimensional structure of a complex of antibody with influenza virus neuraminidase. Nature 1987, 326:358-363.
6. Wilson IA, Skehel JJ, Wiley DC Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289:366-373.
7. Mumford JA, Wood J, Chambers T: Consultation of OIE and WHO experts on progress in surveillance of equine influenza and application to vaccine strain selection. In Report of a meeting held at the Animal Health Trust, Newmarket, UK, 1995.
8. Wharton SA, Weis W, Skehel JJ, Wiley DC Structure, function, and antigenicity of the hemagglutinin of influenza virus 1989, Plenum Press, New York.
9. Skehel JJ, Wiley DC Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000, 69:531-569.
10. Varghese JN, Laver WG, Colman PM Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature 1983, 303:35-40.
11. Gottschalk A Neuraminidase: the specific enzyme of influenza virus and Vibrio cholerae. Biochim Biophys Acta 1957, 23(3):645-646.
12. Air GM, Laver WG The neuraminidase of influenza virus. Proteins 1989, 6:341-356.
13. Bucher D, Palese P The biologically active proteins of influenza virus: neuraminidase 1975, Academic Press, New York.
14. Palese P, Tobita K, Ueda M, Compans RW Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974, 61:397-410.
15. Burnet F Principles of animal virology 1969, Academic Press, New York.
16. Matrosovich MN, Matrosovich TY, Gray T, et al. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004, 78:12665-12667.
17. Pons MW, Schulze IT, Hirst GK, Hauser R Isolation and characterization of the ribonucleoprotein of influenza virus. Virology 1969, 39:250-259.
18. Hirst GK, Pons MW Mechanism of influenza recombination. II. Virus aggregation and its effect on plaque formation by so-called noninfective virus. Virology 1973, 56:620-631.
19. Webster RG, Campbell CH, Granoff A The "in vivo" production of "new" influenza viruses. 3. Isolation of recombinant influenza viruses under simulated conditions of natural transmission. Virology 1973, 51:149-162.
20. Fujii Y, Goto H, Watanabe T, et al. Selective incorporation of influenza virus RNA segments into virions. Proc Natl Acad Sci USA 2003, 100:2002-2007.
21. Gorman OT, Bean WJ, Kawaoka Y, et al. Evolution of influenza A virus nucleoprotein genes: implications for the origins of H1N1 human and classical swine viruses. J Virol 1991, 65:3704-3714.
22. Horimoto T, Kawaoka Y Pandemic threat posed by avian influenza A viruses. Clin Microbiol Rev 2001, 14:129-149.
23. Ito T, Kawaoka Y Avian influenza 1998, Blackwell Science, Oxford.
24. Ito T, Kawaoka Y Host-range barrier of influenza A viruses. Vet Microbiol 2000, 74:71-75.
25. Gammelin M, Mandler J, Scholtissek C Two subtypes of nucleoproteins (NP) of influenza A viruses. Virology 1989, 170:71-80.
26. Webster RG Influenza: an emerging disease. Emerg Infect Dis 1998, 4:436-441.
27. Webster RG, Bean WJ, Gorman OT, et al. Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56:152-179.
28. Olsen CW The emergence of novel swine influenza viruses in North America. Virus Res 2002, 85:199-210.
29. Subbarao K, Swayne D, Olsen CW Epidemiology and control of human and animal influenza 2004, Caister Academic Press, Norfalk, UK.
30. Webby RJ, Webster RG Emergence of influenza A viruses. Philos Trans R Soc B Biol Sci 2001, 356:1817-1828.
31. Tumova B Equine influenza: a segment in influenza virus ecology. Comp Immunol Microbiol Infect Dis 1980, 3:45-59.
32. Alexander DJ, Brown IH Recent zoonoses caused by influenza A viruses. Rev Scientif Techniq 2000, 19:197-225.
33. Chirnside E, Sinclair R, Mumford J Respiratory viral diseases 1998, Saunders, Philadelphia.
34. Coggins L Viral respiratory disease. Vet Clin North Am Large Anim Pract 1979, 1:59-72.
35. Powell DG Viral respiratory disease of the horse. Vet Clin North Am Equine Pract 1991, 7:27-52.
36. Sovinova O, Tumova B, Pouska F, Nemec J Isolation of a virus causing respiratory disease in horses. Acta Virol 1958, 2(1):52-61.
37. Van Maanen C, Cullinane A Equine influenza virus infections: an update. Vet Q 2002, 24:79-94.
38. Webster RG Are equine 1 influenza viruses still present in horses?. Equine Vet J 1993, 25:537-538.
39. Madic J, Martinovic S, Naglic T, et al. Serological evidence for the presence of A/equine-1 influenza virus in unvaccinated horses in Croatia. Vet Rec 1996, 138:68.
40. Lai AC, Chambers TM, Holland RE, et al. Diverged evolution of recent equine-2 influenza (H3N8) viruses in the Western Hemisphere. Arch Virol 2001, 146:1063-1074.
41. Oxburgh L, Klingeborn B Cocirculation of two distinct lineages of equine influenza virus subtype H3N8. J Clin Microbiol 1999, 37:3005-3009.
42. Guthrie AJ, Stevens KB, Bosman PP The circumstances surrounding the outbreak and spread of equine influenza in South Africa. Rev Scientif Techniq 1999, 18:179-185.
43. Uppal PK, Yadav MP, Oberoi MS Isolation of A/Equi-2 virus during 1987 equine influenza epidemic in India. Equine Vet J 1989, 21:364-366.
44. Guo Y, Wang M, Kawaoka Y, et al. Characterization of a new avian-like influenza A virus from horses in China. Virology 1992, 188:245-255.
45. Shortridge KF, Chan WH, Guan Y Epidemiology of the equine influenza outbreak in China, 1993-94. Vet Rec 1995, 136:160-161.
46. Kawaoka Y, Bean WJ, Webster RG Evolution of the hemagglutinin of equine H3 influenza viruses. Virology 1989, 169:283-292.
47. Daly JM, Lai AC, Binns MM, et al. Antigenic and genetic evolution of equine H3N8 influenza A viruses. J Gen Virol 1996, 77:661-671.
48. Ozaki H, Shimizu-Nei A, Sugita S, et al. Antigenic variation among equine H3N8 influenza virus hemagglutinins. Jpn J Vet Res 2001, 48:177-186.
49. Wilson WD Equine influenza. Vet Clin North Am Equine Pract 1993, 9:257-282.
50. Ada GL, Jones PD The immune response to influenza infection. Curr Top Microbiol Immunol 1986, 128:1-54.
51. Hinshaw VS, Naeve CW, Webster RG, et al. Analysis of antigenic variation in equine 2 influenza A viruses. Bull WHO 1983, 61:153-158.
52. Sherman J, Mitchell WR, Martin SW, et al. Epidemiology of equine upper respiratory tract disease on Standardbred racetracks. Can J Comp Med 1979, 43:1-9.
53. Mumford EL, Traub-Dargatz J, Carman J, et al. Occurrence of infectious upper respiratory tract disease and response to vaccination in horses on six sentinel premises in northern Colorado. Equine Vet J 2003, 35:72-77.
54. Morley PS, Townsend HGG, Bodgan JR, Haines DM Descriptive epidemiologic study of disease associated with influenza virus infections during three epidemics in horses. J Am Vet Med Assoc 2000, 216:535-544.
55. Sovinová O, Tumová B, Pouska F, Nemec J Isolation of a virus causing respiratory disease in horses. Acta Virol 1958, 2:51-61.
56. Nyaga PN, Wiggins AD, Priester WA Epidemiology of equine influenza, risk by age, breed and sex. Comp Immunol Microbiol Infect Dis 1980, 3:67-73.
57. Smith BP Influenza in foals. J Am Vet Med Assoc 1979, 174:289-290.
58. Peek SF, Landolt G, Karasin AI, et al. Acute respiratory distress syndrome and fatal interstitial pneumonia associated with equine influenza in a neonatal foal. J Vet Intern Med 2004, 18:132-134.
59. Morley PS, Townsend HGG, Bodgan JR, Haines DM Risk factors for disease associated with influenza virus infections during three epidemics in horses. J Am Vet Med Assoc 2000, 216:545-550.
60. Morley P Viral respiratory disease in athletic horses. Equine sports medicine and surgery: basic and clinical sciences of the equine athlete 2004, 657-673. Saunders, Elsevier Science, London. K.W. Hinchcliff, A.J. Kaneps, R.J. Geor (Eds.).
61. Heldens JG, Weststrate MW, van den Hoven R Area under the curve calculations as a tool to compare the efficacy of equine influenza vaccines: a retrospective analysis of three independent field trials. J Immunol Methods 2002, 264:1-17.
62. Mumford J, Wood JM, Scott AM, et al. Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8). J Hygiene 1983, 90:385-395.
63. Mumford JA, Wood JM, Folkers C, Schild GC Protection against experimental infection with influenza virus A/equine/Miami/63 (H3N8) provided by inactivated whole virus vaccines containing homologous virus. Epidemiol Infect 1988, 100:501-510.
64. Mumford JA, Wilson H, Hannant D, Jessett DM Antigenicity and immunogenicity of equine influenza vaccines containing a Carbomer adjuvant. Epidemiol Infect 1994, 112:421-437.
65. Newton JR, Townsend HG, Wood JL, et al. Immunity to equine influenza: relationship of vaccine-induced antibody in young Thoroughbred racehorses to protection against field infection with influenza A/equine-2 viruses (H3N8). Equine Vet J 2000, 32:65-74.
66. Hannant D, Mumford JA, Jessett DM Duration of circulating antibody and immunity following infection with equine influenza virus. Vet Rec 1988, 122:125-128.
67. Townsend HGG, Lunn DP, Bogdan J, et al: Comparative efficacy of commercial vaccines in naive horses: serologic responses and protection after influenza challenge. Paper presented at 49th Annual AAEP Convention, American Association of Equine Practitioners, New Orleans, 2003.
68. Townsend HG, Penner SJ, Watts TC, et al. Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J 2001, 33:637-643.
69. Heldens JG, Pouwels HG, Loon AA Efficacy and duration of immunity of a combined equine influenza and equine herpesvirus vaccine against challenge with an American-like equine influenza virus (A/equi-2/Kentucky/95). Vet J 2004, 167:150-157.
70. Crouch CF, Daly J, Hannant D, et al. Immune responses and protective efficacy in ponies immunised with an equine influenza ISCOM vaccine containing an "American lineage" H3N8 virus. Vaccine 2004, 23:418-425.
71. Soboll G, Horohov DW, Aldridge BM, et al. Regional antibody and cellular immune responses to equine influenza virus infection, and particle mediated DNA vaccination. Vet Immunol Immunopathol 2003, 94:47-62.
72. Kastner SB, Haines DM, Archer J, Townsend HGG Investigations on the ability of clenbuterol hydrochloride to reduce clinical signs and inflammation associated with equine influenza A infection. Equine Vet J 1999, 31:160-168.
73. Newton JR, Verheyen K, Wood JL, et al. Equine influenza in the United Kingdom in 1998. Vet Rec 1999, 145:449-452.
74. Sarasola P, Taylor DJ, Love S, McKellar QA Secondary bacterial infections following an outbreak of equine influenza. Vet Rec 1992, 131:441-442.
75. Liu KK Report of an equine influenza outbreak which occurred in Hong Kong. Bull Office Int Epizoot 1993, 105:116-117.
76. Barr BS Pneumonia in weanlings. Vet Clin North Am Equine Pract 2003, 19:35-49.
77. Austin SM, Foreman JH, Hungerford LL Case-control study of risk factors for development of pleuropneumonia in horses. J Am Vet Med Assoc 1995, 207:325-330.
78. Mumford JA, Hannant D, Jessett DM Experimental infection of ponies with equine influenza (H3N8) viruses by intranasal inoculation or exposure to aerosols. Equine Vet J 1990, 22:93-98.
79. Uppal PK, Yadav MP Outbreak of equine influenza in India. Vet Rec 1987, 121:569-570.
80. Guo YJ, Guo ZM, Zhang SL, et al. Occurrence of equine influenza in epidemic form in Northeast China. Virus Information Exchange Newslett South East Asia West Pacific 1989, 6:129.
81. Guo Y, Wang M, Zheng S, et al. Aetiologic study of an influenza-like epidemic in horses in China. Acta Virol 1991, 35:190-195.
82. Guo Y, Wang M, Zheng GS, et al. Characterisation of an equine influenza virus responsible for an outbreak in 1993 in China. Equine infectious diseases VII: Proceedings of the Seventh International Conference 1994, 309-400. Newmarket, R&W Publications, Tokyo.
83. Guo Y, Wang M, Kawaoka Y, et al. Characterization of a new avian-like influenza A virus from horses in China. Virology 1992, 188:245-255.
84. Powell DG, Watkins KL, Li PH, Shortridge KF Outbreak of equine influenza among horses in Hong Kong during 1992. Vet Rec 1995, 136:531-536.
85. Wood J, Mumford J Epidemiology of equine influenza. Vet Rec 1992, 130:126.
86. Gudding R, Johansen GI The significance of age and vaccination interval on the protection of horses against equine influenza. Norsk Veterinaertidsskrift 1990, 102:35-36.
87. Bendixen PH, Forssberg P, Silfverberg L Vaccination status and fever in trotting horses in relation to influenza outbreaks in spring 1991. Svensk Vet 1991, 43:713-715.
88. Bendixen PH, Emanuelson U, Forssberg P, Silferberg L Analysis of status of vaccination and development of fever in trotters in Sweden during an outbreak of influenza type A2 (H3N8). Prev Vet Med 1993, 16:95-102.
89. Bridges CB, Kuehnert MJ, Hall CBH Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003, 37:1094-1101.
90. Hota B Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection?. Clin Infect Dis 2004, 39:1182-1189.
91. Boone SA, Gerba CP The occurrence of influenza A virus on household and day care center fomites. J Infect 2005, 51:103-109.
92. Daly JM, Yates PJ, Newton JR, et al. Evidence supporting the inclusion of strains from each of the two co-circulating lineages of H3N8 equine influenza virus in vaccines. Vaccine 2004, 22:4101-4109.
93. Maanen C, Cullinane A Equine influenza virus infections: an update. Vet Q 2002, 24:79-94.
94. Daly JM, Newton JR, Mumford JA Current perspectives on control of equine influenza. Vet Res 2004, 35:411-423.
95. Lany P, Pospisil Z, Zendulkova D, et al. An epidemiological study on an outbreak of equine influenza in the Czech Republic in the autumn of 1995. Vet Med 1997, 42:39-42.
96. Timoney PJ Equine influenza. Comp Immunol Microbiol Infect Dis 1996, 19:205-211.
97. Higgins WP, Gillespie JH, Holmes DF, Robson DS Surveys of equine influenza outbreaks during 1983 and 1984. J Equine Vet Sci 1986, 6:15-19.
98. Wilson WD Equine influenza. Vet Clin North Am Equine Pract 1993, 9:257-282.
99. Sato SB, Kawasaki K, Ohnishi S Hemolytic activity of influenza virus hemagglutinin glycoproteins activated in mildly acidic environments. Proc Natl Acad Sci USA 1983, 80:3153-3157.
100. White J, Matlin K, Helenius A Cell fusion by Semliki Forest, influenza, and vesicular stomatitis viruses. J Cell Biol 1981, 89:674-679.
101. Whittaker GR, Helenius A Nuclear import and export of viruses and virus genomes. Virology 1998, 246:1-23.
102. Donelan NR, Basler CF, Garcia-Sastre A A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol 2003, 77:13257-13266.
103. Garcia-Sastre A Inhibition of interferon-mediated antiviral responses by influenza A viruses and other negative-strand RNA viruses. Virology 2001, 279:375-384.
104. Krug RM, Yuan W, Noah DL, Latham AG Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology 2003, 309:181-189.
105. Bergmann M, Garcia-Sastre A, Carnero E, et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J Virol 2000, 74:6203-6206.
106. Talon J, Horvath CM, Polley R, et al. Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol 2000, 74:7989-7996.
107. Katze MG, He Y, Gale M Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002, 2:675-687.
108. Wang X, Li M, Zheng H, et al. Influenza A virus NS1 protein prevents activation of NF-kappa B and induction of alpha/beta interferon. J Virol 2000, 74:11566-11573.
109. Shapiro GI, Krug RM Influenza virus RNA replication in vitro: synthesis of viral template RNAs and virion RNAs in the absence of an added primer. J Virol 1988, 62:2285-2290.
110. Elder KT, Bye JM, Skehel JJ, et al. In vitro synthesis, glycosylation, and membrane insertion of influenza virus haemagglutinin. Virology 1979, 95:343-350.
111. Hull JD, Gilmore R, Lamb RA Integration of a small integral membrane protein, M2, of influenza virus into the endoplasmic reticulum: analysis of the internal signal-anchor domain of a protein with an ectoplasmic NH2 terminus. J Cell Biol 1988, 106:1489-1498.
112. Boulan ER, Sabatini DD Asymmetric budding of viruses in epithelial monolayers: a model system for study of epithelial polarity. Proc Natl Acad Sci USA 1978, 75:5071-5075.
113. Rudneva IA, Kovaleva VP, Varich NL, et al. Influenza A virus reassortants with surface glycoprotein genes of the avian parent viruses: effects of HA and NA gene combinations on virus aggregation. Arch Virol 1993, 133:437-450.
114. Jin H, Leser GP, Lamb RA The influenza virus hemagglutinin cytoplasmic tail is not essential for virus assembly or infectivity. EMBO J 1994, 13:5504-5515.
115. Jin H, Leser GP, Zhang J, Lamb RA Influenza virus hemagglutinin and neuraminidase cytoplasmic tails control particle shape. EMBO J 1997, 16:1236-1247.
116. Cullinane AA Viral respiratory disease 1997, Saunders, Philadelphia. ed 4.
117. Lin C, Holland RE, Donofrio JC, et al. Caspase activation in equine influenza virus induced apoptotic cell death. Vet Microbiol 2002, 84:357-365.
118. Lin C, Zimmer SG, Lu Z, et al. The involvement of a stress-activated pathway in equine influenza virus-mediated apoptosis. Virology 2001, 287:202-213.
119. Schultz-Cherry S, Dybdahl-Sissoko N, Neumann G, et al. Influenza virus ns1 protein induces apoptosis in cultured cells. J Virol 2001, 75:7875-7881.
120. Martin CM, Kunin CM, Gottlieb LS, et al. Asian influenza A in Boston, 1957-1958. I. Observations in thirty-two influenza-associated fatal cases. Arch Intern Med 1959, 103(4):515-531.
121. Gerber H Clinical features, sequelae and epidemiology of equine influenza 1969, Karger, New York.
122. Willoughby R, Ecker G, McKee S, et al. The effects of equine rhinovirus, influenza virus and herpesvirus infection on tracheal clearance rate in horses. Can J Vet Res 1992, 56:115-121.
123. Mulder J, Hers JF Influenza 1979, Wolters-Noordhoff, Groningen, The Netherlands.
124. Hall WJ, Douglas RG, Hyde RW, et al. Pulmonary mechanics after uncomplicated influenza A infection. Am Rev Respir Dis 1976, 113:141-148.
125. Lamb RA Genes and proteins of the influenza viruses 1989, Plenum Press, New York.
126. Klenk HD, Rott R, Orlich M, Blodorn J Activation of influenza A viruses by trypsin treatment. Virology 1975, 68:426-439.
127. Lazarowitz SG, Choppin PW Enhancement of the infectivity of influenza A and B viruses by proteolytic cleavage of the hemagglutinin polypeptide. Virology 1975, 68:440-454.
128. Bosch FX, Garten W, Klenk HD, Rott R Proteolytic cleavage of influenza virus hemagglutinins: primary structure of the connecting peptide between HA1 and HA2 determines proteolytic cleavability and pathogenicity of Avian influenza viruses. Virology 1981, 113:725-735.
129. Horimoto T, Nakayama K, Smeekens SP, Kawaoka Y Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses. J Virol 1994, 68:6074-6078.
130. Kawaoka Y, Webster RG Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proc Natl Acad Sci USA 1988, 85:324-328.
131. Stieneke-Grober A, Vey M, Angliker H, et al. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J 1992, 11:2407-2414.
132. Yao D, Kuwajima M, Kido H Pathologic mechanisms of influenza encephalitis with an abnormal expression of inflammatory cytokines and accumulation of mini-plasmin. J Med Invest 2003, 50:1-8.
133. Gerber H Clinical features, sequelae and epidemiology of equine influenza. Proceedings of the 2nd International Conference on Equine Infectious Diseases, Paris, 1969 1970, 63-80. Karger Basel, New York. J.T. Bryans (Ed.).
134. Gross DK, Hinchcliff KW, French PS, et al. Effect of moderate exercise on the severity of clinical signs associated with influenza virus infection in horses. Equine Vet J 1998, 30:489-497.
135. Newton JR, Mumford JA Equine influenza. Infectious diseases of livestock 2005, vol 1:766-774. Oxford University Press, Oxford. J.A.W. Coetzer, R.C. Tustin (Eds.).
136. Wattrang E, Jessett DM, Yates P, Fuxler L, Hannant D Experimental infection of ponies with equine influenza A2 (H3N8) virus strains of different pathogenicity elicits varying interferon and interleukin-6 responses. Viral Immunol 2003, 16:57-67.
137. Hannant D, Jessett DM, O'Neill T, Mumford JA Antibody isotype responses in the serum and respiratory tract to primary and secondary infections with equine influenza virus (H3N8). Vet Microbiol 1989, 19:293-303.
138. Nelson KM, Schram BR, McGregor MW, et al. Local and systemic isotype-specific antibody responses to equine influenza virus infection versus conventional vaccination. Vaccine 1998, 16:1306-1313.
139. Renegar KB, Small PAJ Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 1991, 146:1972-1978.
140. Tomoda T, Morita H, Kurashige T, Maassab HF Prevention of influenza by the intranasal administration of cold-recombinant, live-attenuated influenza virus vaccine: importance of interferon-gamma production and local IgA response. Vaccine 1995, 13:185-190.
141. Mazanec MB, Kaetzel CS, Lamm ME, et al. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992, 89:6901-6905.
142. Mazanec MB, Nedrud JG, Kaetzel CS, Lamm ME A three-tiered view of the role of IgA in mucosal defense. Immunol Today 1993, 14:430-435.
143. Mazanec MB, Coudret CL, Fletcher DR Intracellular neutralization of influenza virus by immunoglobulin A anti-hemagglutinin monoclonal antibodies. J Virol 1995, 69:1339-1343.
144. Mazanec MB, Lamm ME, Lyn D, et al. Comparison of IgA versus IgG monoclonal antibodies for passive immunization of the murine respiratory tract. Virus Res 1992, 23:1-12.
145. Soboll G, Nelson KM, Leuthner ES, et al. Mucosal co-administration of cholera toxin and influenza virus hemagglutinin-DNA in ponies generates a local IgA response. Vaccine 2003, 21:3081-3092.
146. Lunn DP, Soboll G, Schram BR, et al. Antibody responses to DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 1999, 17:2245-2258.
147. Sheoran AS, Sponseller BT, Holmes MA, Timoney JF Serum and mucosal antibody isotype responses to M-like protein (SeM) of Streptococcus equi in convalescent and vaccinated horses. Vet Immunol Immunopathol 1997, 59:239-251.
148. Breathnach CC, Yeargan MR, Sheoran AS, Allen GP The mucosal humoral immune response of the horse to infective challenge and vaccination with equine herpesvirus-1 antigens. Equine Vet J 2001, 33:651-657.
149. Morley PS, Hanson LK, Bogdan JR, et al. The relationship between single radial hemolysis, hemagglutination inhibition, and virus neutralization assays used to detect antibodies specific for equine influenza viruses. Vet Microbiol 1995, 45:81-92.
150. Lunn DP, Hussey S, Sebring R, et al. Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in horses after induction of exercise-induced immunosuppression. J Am Vet Med Assoc 2001, 218:900-906.
151. Fu TM, Friedman A, Ulmer JB, et al. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J Virol 1997, 71:2715-2721.
152. Ulmer JB, Fu TM, Deck RR, et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998, 72:5648-5653.
153. Hannant D, Mumford JA Cell mediated immune responses in ponies following infection with equine influenza virus (H3N8): the influence of induction culture conditions on the properties of cytotoxic effector cells. Vet Immunol Immunopathol 1989, 21:327-337.
154. Sun Y, Iglesias E, Samri A, et al. A systematic comparison of methods to measure HIV-1 specific CD8 T cells. J Immunol Methods 2003, 272:23-34.
155. Murali-Krishna K, Altman JD, Suresh M, et al. In vivo dynamics of anti-viral CD8 T cell responses to different epitopes: an evaluation of bystander activation in primary and secondary responses to viral infection. Adv Exp Med Biol 1998, 452:123-142.
156. Breathnach CC, Rudersdorf R, Lunn DP Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination. Vet Immunol Immunopathol 2004, 98:127-136.
157. Breathnach CC, Clark HJ, Clark RC, et al. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 2005, 24:1180-1190.
158. Lunn DP, Soboll G, Schram BR, et al. DNA vaccination of horses using the influenza virus hemagglutinin gene. Vaccine 1999, 14:2245-2258.
159. Toulemonde CE, Daly J, Sindle T, et al. Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom. Vet Rec 2005, 156:367-371.
160. Chen Z, Yoshikawa T, Kadowaki S, et al. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J Gen Virol 1999, 80:2559-2564.
161. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259:1745-1749.
162. Boivin G, Hardy I, Kress A Evaluation of a rapid optical immunoassay for influenza viruses (FLU OIA test) in comparison with cell culture and reverse transcription-PCR. J Clin Microbiol 2001, 39:730-732.
163. Ellis JS, Fleming DM, Zambon MC Multiplex reverse transcription-PCR for surveillance of influenza A and B viruses in England and Wales in 1995 and 1996. J Clin Microbiol 1997, 35:2076-2082.
164. Fouchier RA, Bestebroer TM, Herfst S, et al. Detection of influenza A viruses from different species by PCR amplification of conserved sequences in the matrix gene. J Clin Microbiol 2000, 38:4096-4101.
165. Mumford JA The diagnosis and control of equine influenza. Proc Am Assoc Equine Pract 1990, 36:377.
166. Flint SJ, Enquist LW, Krug RM, et al. Virus cultivation, detection and genetics 2000, ASM Press, Washington, DC.
167. Ilobi CP, Henfrey R, Robertson JS, et al. Antigenic and molecular characterization of host cell-mediated variants of equine H3N8 influenza viruses. J Genl Virol 1994, 75:669-673.
168. Katz JM, Naeve CW, Webster RG Host cell-mediated variation in H3N2 influenza viruses. Virology 1987, 156:386-395.
169. Robertson JS, Naeve CW, Webster RG, et al. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985, 143:166-174.
170. Schild GC, Oxford JS, de Jong JC, Webster RG Evidence for host-cell selection of influenza virus antigenic variants. Nature 1983, 303:706-709.
171. Endo Y, Carroll KN, Ikizler MR, Wright PF Growth of influenza A virus in primary, differentiated epithelial cells derived from adenoids. J Virol 1996, 70:2055-2058.
172. Frank AL, Couch RB, Griffis CA, Baxter BD Comparison of different tissue cultures for isolation and quantitation of influenza and parainfluenza viruses. J Clin Microbiol 1979, 10:32-36.
173. Govorkova EA, Murti G, Meignier B, et al. African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses. J Virol 1996, 70:5519-5524.
174. Lau SC, Scholtissek C Abortive infection of Vero cells by an influenza A virus (FPV). Virology 1995, 212:225-231.
175. Reina J, Fernandez-Baca V, Blanco I, Munar M Comparison of Madin-Darby canine kidney cells (MDCK) with a green monkey continuous cell line (Vero) and human lung embryonated cells (MRC-5) in the isolation of influenza A virus from nasopharyngeal aspirates by shell vial culture. J Clin Microbiol 1997, 35:1900-1901.
176. Huang YT, Turchek BM Mink lung cells and mixed mink lung and A549 cells for rapid detection of influenza virus and other respiratory viruses. J Clin Microbiol 2000, 38:422-423.
177. Hannant D, Mumford JA Equine influenza 1996, Elsevier Science, St Louis.
178. Ilobi CP, Nicolson C, Taylor J, et al. Direct sequencing of the HA gene of clinical equine H3N8 influenza virus and comparison with laboratory derived viruses. Arch Virol 1998, 143:891-901.
179. Rott R, Orlich M, Klenk HD, et al. Studies on the adaptation of influenza viruses to MDCK cells. EMBO J 1984, 3:3329-3332.
180. Wiley DC, Wilson IA, Skehel JJ Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981, 289:373-378.
181. Landolt GA, Karasin AI, Hofer C, et al. Use of real-time reverse transcriptase polymerase chain reaction assay and cell culture methods for detection of swine influenza A viruses. Am J Vet Res 2005, 66:119-124.
182. Schultz-Cherry S, Dybdahl-Sissoko N, McGregor M, Hinshaw VS Mink lung epithelial cells: unique cell line that supports influenza A and B virus replication. J Clin Microbiol 1998, 36:3718-3720.
183. Chomel JJ, Thouvenot D, Onno M, et al. Rapid diagnosis of influenza infection of NP antigen using an immunocapture ELISA test. J Virol Methods 1989, 25:81-91.
184. Cook RF, Sinclair R, Mumford JA Detection of influenza nucleoprotein antigen in nasal secretions from horses infected with A/equine influenza (H3N8) viruses. J Virol Methods 1988, 20:1-12.
185. Livesay GJ, O'Neill T, Hannant D, et al. The outbreak of equine influenza (H3N8) in the United Kingdom in 1989: diagnostic use of an antigen capture ELISA. Vet Rec 1993, 133:515-519.
186. Adam EN, Morley PS, Chmielewski KE, et al. Detection of cold-adapted vaccine-strain influenza virus using two commercial assays. Equine Vet J 2002, 34:400-404.
187. Chambers TM, Shortridge KF, Li PH, et al. Rapid diagnosis of equine influenza by the Directigen FLU-A enzyme immunoassay. Vet Rec 1994, 135:275-279.
188. Morley PS, Bogdan JR, Townsend HG, Haines DM Evaluation of Directigen Flu-A assay for detection of influenza antigen in nasal secretions of horses. Equine Vet J 1995, 27:131-134.
189. Townsend HGG, Moore SL, Bogdan JR: Evaluation of an optical immunoassay for the diagnosis of equine influenza. In Proceedings of the 9th Symposium of the International Society for Veterinary Epidemiology and Economics, 2000.
190. Herrmann B, Larsson C, Zweygberg BW Simultaneous detection and typing of influenza viruses A and B by a nested reverse transcription-PCR: comparison to virus isolation and antigen detection by immunofluorescence and optical immunoassay (FLU OIA). J Clin Microbiol 2001, 39:134-138.
191. Bej AK, Mahbubani MH, Atlas RM Amplification of nucleic acids by polymerase chain reaction (PCR) and other methods and their applications. Crit Rev Biochem Mol Biol 1991, 26:301-334.
192. Wagar EA Direct hybridization and amplification applications for the diagnosis of infectious diseases. J Clin Lab Anal 1996, 10:312-325.
193. Wolcott MJ Advances in nucleic acid-based detection methods. Clin Microbiol Rev 1992, 5:370-386.
194. Magnard C, Valette M, Aymard M, Lina B Comparison of two nested PCR, cell culture, and antigen detection for the diagnosis of upper respiratory tract infections due to influenza viruses. J Med Virol 1999, 59:215-220.
195. Wallace LA, McAulay KA, Douglas JD, et al. Influenza diagnosis: from dark isolation into the molecular light, West of Scotland Respiratory Virus Study Group. Journal of Infection 1999, 39:221-226.
196. Spackman E, Senne DA, Myers TJ, et al. Development of a real-time reverse transcriptase PCR assay for type A influenza virus and the avian H5 and H7 hemagglutinin subtypes. J Clin Microbiol 2002, 40:3256-3260.
197. Jackson DP, Hayden JD, Quirke P Extraction of nucleic acid from fresh and archival material 1991, Oxford University Press, Oxford, UK.
198. Steininger C, Kundi M, Aberle SW, et al. Effectiveness of reverse transcription-PCR, virus isolation, and enzyme-linked immunosorbent assay for diagnosis of influenza A virus infection in different age groups. J Clin Microbiol 2002, 40:2051-2056.
199. Al-Soud WA, Radstrom P Purification and characterization of PCR-inhibitory components in blood cells. J Clin Microbiol 2001, 39:485-493.
200. Habib-Bein NF, Beckwith WH, et al. Comparison of SmartCycler real-time reverse transcription-PCR assay in a public health laboratory with direct immunofluorescence and cell culture assays in a medical center for detection of influenza A virus. J Clin Microbiol 2003, 41:3597-3601.
201. Stauffer F, Haber H, Rieger A, et al. Genus level identification of mycobacteria from clinical specimens by using an easy-to-handle Mycobacterium-specific PCR assay. J Clin Microbiol 1998, 36:614-617.
202. Zou S A practical approach to genetic screening for influenza virus variants. J Clin Microbiol 1997, 35:2623-2627.
203. Zou S, Stansfield C, Bridge J Identification of new influenza B virus variants by multiplex reverse transcription-PCR and the heteroduplex mobility assay. J Clin Microbiol 1998, 36:1544-1548.
204. Fan J, Henrickson KJ, Savatski LL Rapid simultaneous diagnosis of infections with respiratory syncytial viruses A and B, influenza viruses A and B, and human parainfluenza virus types 1, 2, and 3 by multiplex quantitative reverse transcription-polymerase chain reaction-enzyme hybridization assay (Hexaplex). Clin Infect Dis 1998, 26:1397-1402.
205. Grondahl B, Puppe W, Hoppe A, et al. Rapid identification of nine microorganisms causing acute respiratory tract infections by single-tube multiplex reverse transcription-PCR: feasibility study. J Clin Microbiol 1999, 37:1-7.
206. Stockton J, Ellis JS, Saville M, et al. Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol 1998, 36:2990-2995.
207. Van Elden LJ, van Essen GA, Boucher CA, et al. Clinical diagnosis of influenza virus infection: evaluation of diagnostic tools in general practice. Br J Gen Pract 2001, 51:630-634.
208. Mumford J Progress in the control of influenza 1991, R&W Publications, Newmarket, UK.
209. Wood JM, Gaines-Das RE, Taylor J, Chakraverty P Comparison of influenza serological techniques by international collaborative study. Vaccine 1994, 12:167-174.
210. Hamilton F Studies on the single radial hemolysis technique for the assay of equine influenza virus, adenovirus and herpesvirus 1 antibodies 1978, Veterinary Publications, Princeton, NJ.
211. Hannant D, Jessett DM, O'Neill T, Mumford JA Antibody isotype responses in the serum and respiratory tract to primary and secondary infections with equine influenza virus (H3N8). Vet Microbiol 1989, 19:293-303.
212. Plateau E, Cruciere C Study on radial hemolysis method for the detection of anti influenza equi antibodies in equine sera: reliability and expression of the results. Zentralblatt Vet Reihe B 1983, 30:512-520.
213. Mumford JA, Wood JM, Folkers C, Schild GC Protection against experimental infection with influenza virus A/equine/Miami/63 (H3N8) provided by inactivated whole virus vaccines containing homologous virus. Epidemiol Infect 1988, 100:501-510.
214. Mumford JA, Wood JM, Scott AM, et al. Studies with inactivated equine influenza vaccine. 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8). J Hygiene 1983, 90:385-395.
215. Garin B, Plateau E, Gillet-Forin S Serological diagnosis of influenza A infections in the horse by enzyme immunoassay: comparison with the complement fixation test. Vet Immunol Immunopathol 1986, 13:357-363.
216. Sugiura T, Sugita S, Imagawa H, et al. Serological diagnosis of equine influenza using the hemagglutinin protein produced in a baculovirus expression system. J Virol Methods 2001, 98:1-8.
217. Ozaki H, Sugiura T, Sugita S, et al. Detection of antibodies to the nonstructural protein (NS1) of influenza A virus allows distinction between vaccinated and infected horses. Vet Microbiol 2001, 82:111-119.
218. Birch-Machin I, Rowan A, Pick J, et al. Expression of the nonstructural protein NS1 of equine influenza A virus: detection of anti-NS1 antibody in post infection equine sera. J Virol Methods 1997, 65:255-263.
219. Nakajima K, Nobusawa E, Nakajima S Evolution of the NS genes of the influenza A viruses. II. Characteristics of the amino acid changes in the NS1 proteins of the influenza A viruses. Virus Genes 1990, 4:15-26.
220. Nelson KM Antibody isotype responses and protective immunity resulting from equine influenza virus infection or conventional vaccination 1995, University of Wisconsin, Madison, (Master of Science thesis).
221. Ainsworth DM, Hackett RP Disorders of the respiratory system. Equine internal medicine 2004, 289-354. Saunders, Philadelphia. ed 2. S.M. Reed, W.M. Bayly, D.C. Sellon (Eds.).
222. Schmidt AC Antiviral therapy for influenza: a clinical and economic comparative review. Drugs 2004, 64:2031-2046.
223. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355:1845-1850. (erratum, 356:1856, 2000).
224. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000, 283:1016-1024. (see comment).
225. Van Voris LP, Newell PM Antivirals for the chemoprophylaxis and treatment of influenza. Semin Respir Infect 1992, 7:61-70.
226. Hay AJ The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992, 3:21.
227. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985, 4:3021-3024.
228. Belshe RB, Burk B, Newman F, et al. Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance. J Infect Dis 1989, 159:430-435.
229. Hayden FG Antiviral agents 2001, McGraw-Hill, New York. ed 10.
230. Shiraishi K, Mitamura K, Sakai-Tagawa Y, et al. High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza. J Infect Dis 2003, 188:57-61.
231. Rees WA, Harkins JD, Woods WE, et al. Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet J 1997, 29:104-110. (see comment).
232. Keyser LA, Karl M, Nafziger AN, Bertino JS Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients. Arch Intern Med 2000, 160:1485-1488.
233. Rees WA, Harkins JD, Lu M, et al. Pharmacokinetics and therapeutic efficacy of rimantadine in horses experimentally infected with influenza virus A2. Am J Vet Res 1999, 60:888-894.
234. Hayden FG, Monto AS Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother 1986, 29:339-341.
235. Van Voris LP, Betts RF, Hayden FG, et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981, 245:1128-1131.
236. Wingfield WL, Pollack D, Grunert RR Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man. N Engl J Med 1969, 281:579-584.
237. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989, 321:1696-1702.
238. Sweet C, Hayden FG, Jakeman KJ, et al. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991, 164:969-972.
239. Webster RG, Kawaoka Y, Bean WJ Vaccination as a strategy to reduce the emergence of amantadine- and rimantadine-resistant strains of A/Chick/Pennsylvania/83 (H5N2) influenza virus. J Antimicrob Chemother 1986, 18(suppl B):157-164.
240. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998, 26:1418-1424.
241. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991, 134:988-997.
242. Munoz FM, Campbell JR, Atmar RL, et al. Influenza A virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J 1999, 18:811-815.
243. Mumford JA, Jessett DM, Rollinson EA, et al. Duration of protective efficacy of equine influenza immunostimulating complex/tetanus vaccines. Vet Rec 1994, 134:158-162.
244. Mumford JA, Jessett D, Dunleavy U, et al. Antigenicity and immunogenicity of experimental equine influenza ISCOM vaccines. Vaccine 1994, 12:857-863.
245. Mumford JA Progress in the control of equine influenza. Equine infectious diseases VI: Proceedings of the Sixth International Conference 1992, 207-217. R&W Publications, Newmarket, UK. W. Plowright, P.D. Rossdale, J.F. Wade (Eds.).
246. Mumford JA, Wood J Establishing an acceptability threshold for equine influenza vaccines. Dev Biol Standard 1992, 79:137-146.
247. Newton JR, Daly JM, Mumford JA: Failure of recent vaccination to prevent infection of racehorses in Newmarket, UK with a Kentucky/02-lide H3N8 influenza virus. Third International Veterinary Vaccines and Diagnostics Conference, Guelph, Ontario, 2003, p 33.
248. Grogan EH, McDonnell SM Behavioral responses to two intranasal vaccine applicators in horses and ponies. J Am Vet Med Assoc 2005, 226:1689-1693.
249. Chambers TM, Holland RE, Tudor LR A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet J 2001, 33:630-636.
250. Wilson WD, Kanara E, Spensley MS, et al. Guidelines for vaccination of horses. J Am Vet Med Assoc 1995, 207:426-431.
251. Lunn DP, Townsend HGG Equine vaccination. Vet Clin North Am Equine Pract 2000, 16:199-226.
252. Wilson WD, Mihalyi JE, Hussey S, Lunn DP Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination. Equine Vet J 2001, 33:644-650.
253. Townsend HGG, Morley PS, Newton JR Measuring serum antibody as a method of predicting infection and disease in horses during outbreaks of influenza. Equine infectious diseases VIII: Proceedings of the Eighth International Conference 1999, 33-37. R&W Publications, Newmarket, UK, Dubai, 1998. U. Wernery, J.F. Wade, J.A. Mumford, O.R. Kaaden (Eds.).
254. Mumford JA The equine influenza surveillance program. Adv Vet Med Vet Vaccines Diagnostics 1999, 41:379-387.
255. Crawford PC, Dubovi EJ, Castleman WL, et al. Transmission of equine influenza virus to dogs. Science 2005, 310:482-485.
256. Kasel JA, Couch RB Experimental infection in man and horses with influenza A viruses. Bull WHO 1969, 41:447-452.
257. Houser RE, Heuschele WP Evidence of prior infection with influenza A/Texas/77 (H3N2) virus in dogs with clinical parainfluenza. Can J Comp Med 1980, 44:396-402.
258. Todd JD, Cohen D Studies of influenza in dogs. I. Susceptibility of dogs to natural and experimental infection with human A2 and B influenza virus. Am J Epidemiol 1968, 87:426-439.
259. Chang CP, New AE, Taylor JF, Chiang HS Influenza virus isolations from dogs during a human epidemic in Taiwan. Int J Zoonoses 1976, 3:61-64.
260. Nikitin T, Cohen D, Todd JD, Lief FS Epidemiological studies of A/Hong Kong/68 virus infection in dogs. Bull WHO 1972, 47:471-479.